Seredenin S B, Viglinskaia A O, Kolyvanov G B, Litvin A A, Kravtsova O Iu, Zherdev V P
Eksp Klin Farmakol. 2007 Mar-Apr;70(2):59-64.
Afobazole pharmacokinetics was studied after the administration via different ways in rats. After oral administration, afobazole is subject to intensive biotransformation with the formation of several metabolites (M-6, M-7, and M-11). The drug and its metabolites were detected in the blood plasma for 3 h and characterized by a high elimination rate after both oral and intravenous administration. Afobazole and its main metabolite (M-11) had a medium rate of permeability into brain (the target organ): the tissue availability was 0.584 for afobazole and 0.793 for M-11. The absolute bioavailability of afobazole upon oral administration was 43.6% for. Afobazole was completely absorbed from the gastrointestinal tract of rats and characterized by the first-pass effect, after which more than 40% of administered dose entered the circulation. The parent compound was determined in extremely low amounts in urine and feces: its content in 24-h urine on the average did not exceed 0.07% of the administered dose; in 24-h feces, it did not exceed 0.05 % after intravenous administration and 0.01% after oral administration).
在大鼠中通过不同途径给药后研究了阿伏苯唑的药代动力学。口服给药后,阿伏苯唑会经历强烈的生物转化,形成几种代谢产物(M-6、M-7和M-11)。药物及其代谢产物在血浆中可检测3小时,口服和静脉给药后均具有高消除率。阿伏苯唑及其主要代谢产物(M-11)进入脑(靶器官)的渗透率中等:阿伏苯唑的组织利用率为0.584,M-11为0.793。口服给药时阿伏苯唑的绝对生物利用度为43.6%。阿伏苯唑从大鼠胃肠道完全吸收,具有首过效应,给药剂量的40%以上进入循环。母体化合物在尿液和粪便中的含量极低:其在24小时尿液中的含量平均不超过给药剂量的0.07%;在24小时粪便中,静脉给药后不超过0.05%,口服给药后不超过0.01%。